Nyxoah (NASDAQ:NYXH) Shares Up 1.2% – Still a Buy?

Nyxoah S.A. (NASDAQ:NYXH) rose 1.2% during mid-day trading on Friday . The company traded as high as $9.16 and last traded at $9.15. Approximately 31,729 shares traded hands during trading, a decline of 53% from the average daily volume of 66,965 shares. The stock had previously closed at $9.04.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on NYXH shares. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $16.00 price objective on shares of Nyxoah in a report on Tuesday, November 5th. HC Wainwright reaffirmed a “buy” rating and issued a $17.00 price target on shares of Nyxoah in a report on Friday, December 13th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, Nyxoah currently has a consensus rating of “Buy” and an average target price of $17.00.

Nyxoah Trading Up 1.2 %

The firm has a market capitalization of $228.20 million, a PE ratio of -4.89 and a beta of 1.35. The company’s fifty day simple moving average is $8.44 and its 200-day simple moving average is $8.47. The company has a debt-to-equity ratio of 0.21, a current ratio of 5.28 and a quick ratio of 4.95.

Hedge Funds Weigh In On Nyxoah

A hedge fund recently bought a new position in Nyxoah stock. CVI Holdings LLC acquired a new stake in Nyxoah S.A. (NASDAQ:NYXH) in the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor acquired 183,590 shares of the company’s stock, valued at approximately $1,292,000. Nyxoah comprises approximately 1.2% of CVI Holdings LLC’s investment portfolio, making the stock its 13th biggest holding. CVI Holdings LLC owned about 0.74% of Nyxoah at the end of the most recent reporting period.

Nyxoah Company Profile

Nyxoah SA, a medical technology company, focuses on the development and commercialization of solutions to treat sleep disordered breathing conditions. The company’s lead solution comprises Genio system, a CE-Marked, patient-centric, and hypoglossal neurostimulation therapy to treat moderate to severe obstructive sleep apnea.